Literature DB >> 28065893

Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: a new emerging superbug?

Mariana I D S Xisto1,2, Rita D F Caramalho1, Débora A S Rocha3, Antonio Ferreira-Pereira3, Bettina Sartori1, Eliana Barreto-Bergter2, Maria L Junqueira4, Cornelia Lass-Flörl1, Michaela Lackner1.   

Abstract

Objectives: Candidaemia is a public health problem mainly in hospitalized individuals worldwide. In Brazil, Candida albicans is the most prevalent species that causes candidaemia, followed by Candida tropicalis and Candida parapsilosis . Few data on the abundance of antifungal resistance are available for Latin America.
Methods: We analysed the frequency of azole and echinocandin resistance in Candida isolates ( n  =   75) collected between 2012 and 2014 at the University Hospital of Federal University of Juiz de Fora (Brazil). The primary targets erg11 (azoles) and fks1 (echinocandins) were sequenced and modelled at the protein level. Antifungal susceptibility testing was performed according to CLSI (M27-A3 and M27-S4) and according to EUCAST.
Results: The three most frequent species were C. albicans (38.0%), C. tropicalis (30.0%) and Candida glabrata (17.0%). Azole resistance was observed in 27.0% of all Candida isolates, while 20.0% of all isolates were echinocandin resistant. A novel mutation in erg11 at location K143R was found to be associated with phenotypically pan-azole-resistant C. tropicalis isolates. This mutation maps near the active binding site of erg11 and is likely to confer pan-azole resistance to C. tropicalis . Conclusions: A novel point mutation (K143R) located in the erg11 gene of C. tropicalis was found in pan-azole-resistant strains. According to our protein homology model, it is very likely that the mutation K143R causes pan-azole resistance in C. tropicalis . Moreover, an up-regulation of ABC transporters was observed, which can add up to a pan-azole-resistant phenotype.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28065893     DOI: 10.1093/jac/dkw558

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.

Authors:  Shaoming Lin; Ruilan Chen; Song Zhu; Huijun Wang; Lianfang Wang; Jian Zou; Jingdong Yan; Xiangdong Zhang; Dimitrios Farmakiotis; Xiaojiang Tan; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2018-03-23       Impact factor: 2.574

2.  Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy.

Authors:  Ziauddin Khan; Suhail Ahmad; Eiman Mokaddas; Jacques F Meis; Leena Joseph; Aneesa Abdullah; Sandhya Vayalil
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

3.  A CTG Clade Candida Yeast Genetically Engineered for the Genotype-Phenotype Characterization of Azole Antifungal Resistance in Human-Pathogenic Yeasts.

Authors:  Isabelle Accoceberry; Amandine Rougeron; Nicolas Biteau; Pauline Chevrel; Valérie Fitton-Ouhabi; Thierry Noël
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

4.  Mechanisms of azole antifungal resistance in clinical isolates of Candida tropicalis.

Authors:  Saikat Paul; Dipika Shaw; Himanshu Joshi; Shreya Singh; Arunaloke Chakrabarti; Shivaprakash M Rudramurthy; Anup K Ghosh
Journal:  PLoS One       Date:  2022-07-12       Impact factor: 3.752

Review 5.  The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors.

Authors:  Jingxiang Zhang; Liping Li; Quanzhen Lv; Lan Yan; Yan Wang; Yuanying Jiang
Journal:  Front Microbiol       Date:  2019-04-24       Impact factor: 5.640

6.  Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016.

Authors:  Michael A Pfaller; Daniel J Diekema; John D Turnidge; Mariana Castanheira; Ronald N Jones
Journal:  Open Forum Infect Dis       Date:  2019-03-15       Impact factor: 3.835

7.  Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent Candida spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability.

Authors:  A Espinel-Ingroff; M Sasso; J Turnidge; M Arendrup; F Botterel; N Bourgeois; B Bouteille; E Canton; S Cassaing; E Dannaoui; M Dehais; L Delhaes; D Dupont; A Fekkar; J Fuller; G Garcia-Effron; J Garcia; G M Gonzalez; N P Govender; H Guegan; J Guinea; S Houzé; C Lass-Flörl; T Pelaez; A Forastiero; M Lackner; R Magobo
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

8.  MDR1 overexpression combined with ERG11 mutations induce high-level fluconazole resistance in Candida tropicalis clinical isolates.

Authors:  Longyang Jin; Zhuorui Cao; Qi Wang; Yichen Wang; Xiaojuan Wang; Hongbin Chen; Hui Wang
Journal:  BMC Infect Dis       Date:  2018-04-10       Impact factor: 3.090

9.  Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates.

Authors:  Amir Arastehfar; Farnaz Daneshnia; Ahmed Hafez; Sadegh Khodavaisy; Mohammad-Javad Najafzadeh; Arezoo Charsizadeh; Hossein Zarrinfar; Mohammadreza Salehi; Zahra Zare Shahrabadi; Elahe Sasani; Kamiar Zomorodian; Weihua Pan; Ferry Hagen; Macit Ilkit; Markus Kostrzewa; Teun Boekhout
Journal:  Med Mycol       Date:  2020-08-01       Impact factor: 4.076

10.  Limited ERG11 Mutations Identified in Isolates of Candida auris Directly Contribute to Reduced Azole Susceptibility.

Authors:  Kelley R Healey; Milena Kordalewska; Cristina Jiménez Ortigosa; Ashutosh Singh; Indira Berrío; Anuradha Chowdhary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.